Table 2 Characteristics of ovarian stimulation, oocyte retrieval, fertilization, embryo development and embryo freezing.

From: Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol

Characteristics

Corifollitropin alfa/PPOS protocol (n = 173)

Corifollitropin alfa/GnRHant protocol (n = 160)

P value

Stimulation

Duration of GnRHant injections (days)

0 ± 0

6.8 ± 1.4

0.000

Duration of additional gonadotropin stimulation (days)

3.9 ± 1.3

3.8 ± 1.4

0.240

Total dose of additional gonadotropin consumption (IU)

497.7 ± 233.1

478.4 ± 301.8

0.511

Average dose of additional daily gonadotropin consumption (IU)

124.3 ± 32.6

120.7 ± 36.9

0.344

Serum hormonal level on ovulation trigger day

E2 (pg/mL)

7694.5 ± 3219.5

7829.9 ± 3266.1

0.704

LH (IU/L)

1.5 ± 1.2

1.3 ± 1.0

0.242

Progesterone (ng/mL)

2.1 ± 0.9

2.0 ± 0.9

0.589

Incidence of premature LH surge (%)

0 (0/173)

0 (0/160)

 

Incidence of OHSS (%)

0 (0/173)

0 (0/160)

 

Oocyte retrieval

No. of oocytes retrieved

20.7 ± 6.3

19.8 ± 6.2

0.195

Metaphase II oocyte rate (%)

78.8 ± 15.0

78.1 ± 15.8

0.688

Fertilization rate (%)

73.9 ± 16.7

73.6 ± 17.7

0.883

Embryo development (day 5/6)

No. of good blastocyst

4.1 ± 3.0

4.0 ± 3.1

0.673

No. of blastocyst frozen

6.9 ± 4.8

6.7 ± 4.8

0.655

  1. Values are expressed as either mean ± standard deviation or percentage. PPOS progestin primed ovarian stimulation, GnRHant GnRH antagonist, E2 estradiol, LH luteinizing hormone, OHSS ovarian hyperstimulation syndrome.